DNA X
SONM · NASDAQ
Key indicators
SONM profitability and balance sheet ratios
EPS -$0.9231 in Q2 FY26, against -$14.15 a year earlier.
| Period | EPS |
|---|---|
| Q2 FY24 | -$1.41 |
| Q3 FY24 | -$0.518 |
| Q4 FY24 | -$79.43 |
| Q1 FY25 | $1.40 |
| Q2 FY25 | -$14.15 |
| Q3 FY25 | -$4.83 |
| Q1 FY26 | $5.01 |
| Q2 FY26 | -$0.9231 |
Where the money went
Q3 FY25, from revenue to net income
DNA X brought in $16.2M of revenue in Q3 FY25, +7.9% on a year earlier. It made a net loss of $4.8M.
- Revenue
- $16.2M
- Costs, expenses and taxes
- $21.0M
- Net income
- −$4.8M
- Net margin
- -29.3%
Income statement
Revenue and profit by reporting period
| Line item | Q3 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|
| Revenue | $16.2M | $0.0M | $0.0M |
| Gross profit | $1.8M | $0.0M | $0.0M |
| Operating income | −$4.0M | −$3.6M | −$1.3M |
| Net income | −$4.8M | $6.3M | −$1.2M |
| Diluted EPS | -$4.83 | $5.01 | -$0.92 |
Balance sheet
What the company owns and owes at period end
| Line item | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Total assets | $43.9M | $4.8M | $4.5M |
| Total liabilities | $50.6M | $4.9M | $5.7M |
| Shareholder equity | −$6.7M | −$0.1M | −$1.2M |
| Cash and short-term investments | $1.3M | $1.2M | $0.9M |
| Total debt | $5.1M | $1.1M | $2.4M |
Cash flow
Cash in and out from operations, investing and financing
| Line item | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|
| Operating cash flow | −$2.0M | −$3.5M | −$2.0M |
| Investing cash flow | $0.0M | $3.4M | −$0.1M |
| Financing cash flow | $1.2M | $0.0M | $1.8M |
| Capital expenditure | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$2.0M | −$3.5M | −$2.0M |
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.